Barriers to the management of alcohol use disorder and alcohol-associated liver disease: strategies to implement integrated care models
- PMID: 35026172
- PMCID: PMC12457915
- DOI: 10.1016/S2468-1253(21)00191-6
Barriers to the management of alcohol use disorder and alcohol-associated liver disease: strategies to implement integrated care models
Abstract
Despite its increased recognition as a major public health issue, alcohol use disorder is mostly underdiagnosed and undertreated. The undertreatment and underdiagnosis of alcohol use disorder is most concerning in the management of patients with alcohol-associated liver disease, which is one of the main medical consequences of chronic and excessive alcohol use. Dual pathology (alcohol use disorder and alcohol-associated liver disease) requires multidisciplinary care involving hepatologists and addiction specialists. Such integrated care models are widely accepted as optimal care for treating comorbid medical and mental health conditions. However, the implementation of such models in clinical practice is challenging and often represents the exception, rather than the rule, in managing patients with alcohol use disorder and alcohol-associated liver disease. Barriers at the patient, clinician, and system levels are encountered in treating patients with alcohol use disorder and alcohol-associated liver disease. In this Viewpoint, we synthesise the emerging literature on the potential barriers encountered in caring for patients with alcohol-associated liver disease and alcohol use disorder and focus on how integrated models of care could overcome these barriers. We provide our perspective on why these barriers exist and propose strategies to overcome them.
Copyright © 2022 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests LL reports honoraria from the UK Medical Council on Alcoholism (Editor-in-Chief for Alcohol and Alcoholism); receives book royalties from Routledge; funding from the Intramural Research Program of the National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism (ZIA-DA000635 and ZIA-AA000218); and employment by the National Institutes of Health. AKS reports personal fees from Gilead, Medscape Gastroenterology, CLD Foundation, Up-to-Date, and ACG; non-financial support from American Association for the Study of Liver Diseases and American Porphyria Foundation; and grants from National Institute on Alcohol Abuse and Alcoholism and National Institute of Diabetes and Digestive and Kidney Diseases.
Figures
Comment in
-
Digging deeper into alcohol-related deaths.Lancet Gastroenterol Hepatol. 2022 Feb;7(2):107. doi: 10.1016/S2468-1253(21)00479-9. Lancet Gastroenterol Hepatol. 2022. PMID: 35026165 No abstract available.
References
-
- Axley PD, Richardson CT, Singal AK. Epidemiology of Alcohol Consumption and Societal Burden of Alcoholism and Alcoholic Liver Disease. Clin Liver Dis. 2019;23(1):39–50. - PubMed
-
- Caputo F, Domenicali M, Bernardi M. Diagnosis and Treatment of Alcohol Use Disorder in Patients With End-Stage Alcoholic Liver Disease. Hepatology (Baltimore, Md). 2019;70(1):410–7. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
